Therapeutical Class：2nd generation cephalosporins, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): not for Enterococci, MRSA, Listeria; G(-): E. coli, H. influenzae, Klebsiella, Proteus, N. gonorrheae, not for Pseudomonas and Serratia.

Administraton：IM or IV:

Adults and children>13 yrs: 0.75-1.5 g q6-8h, max 6 g/day.

Intra-abdominal infection: 1.5 g q8h.

Uncomplicated UTI, uncomplicated skin structure infection: 0.75g q8h.

Surgical prophylaxis: 1.5 g prior to procedure.

Renal impairment: Ccr 10-20 ml/min,0.75-1.5g q12h;

Ccr <10 ml/min,0.75-1.5g qd.

Children 3 months to 12 years: 75-150 mg/kg/day divided every 8 hours(max: 6 g/day).

PO: adults: 250-500 mg bid.

PO:for uncomplicated gonorrhea: 1g single dose.

PO:for children: 125-250 mg bid.

Adverse Effect：Diarrhea (>10%), allergy (rash, etc.1-10%), decreased hemoglobin and hematocrit, neutropenia, thrombocytopenia, eosinophilia, elevated AST, ALT, LDH, bilirubin and alkaline phosphatase, phlebitis, , nausea and vomiting.

Pregnancy Risk：BSupply： Furoxime XE “Furoxime”  Inj 1.5gm(福樂欣注射劑 信東) ＜10909＞